Jun. 22 at 10:15 PM
$PFE Pfizer announced that sigvotatug vedotin, the ADC acquired through its
$43B Seagen deal, failed to significantly improve overall survival vs.
docetaxel in a Phase 3 advanced non-small cell lung cancer trial. The company will continue its development, including an ongoing Phase 3 study in combination with Merck’s Keytruda for 1L lung cancer.